Rep. Robert B. Aderholt Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock

Representative Robert B. Aderholt (R-Alabama) recently sold shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on September 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on July 28th.

GSK Stock Up 2.4%

Shares of NYSE:GSK opened at $41.46 on Friday. The stock has a market cap of $84.44 billion, a P/E ratio of 19.19, a P/E/G ratio of 2.02 and a beta of 0.53. The firm has a fifty day moving average price of $38.69 and a 200 day moving average price of $38.44. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $43.62.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same quarter in the prior year, the business earned $0.43 EPS. GSK’s quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.1%. GSK’s dividend payout ratio is currently 77.78%.

Wall Street Analyst Weigh In

Several brokerages recently commented on GSK. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $37.38.

Hedge Funds Weigh In On GSK

Several hedge funds have recently added to or reduced their stakes in the business. Dodge & Cox grew its holdings in shares of GSK by 14.9% during the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock worth $3,046,972,000 after buying an additional 10,210,921 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.4% during the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock worth $1,203,395,000 after buying an additional 1,306,590 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock worth $995,929,000 after buying an additional 446,360 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of GSK by 2.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock worth $299,163,000 after buying an additional 155,392 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of GSK by 5.7% during the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock worth $293,692,000 after buying an additional 411,869 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Aderholt

Robert Aderholt (Republican Party) is a member of the U.S. House, representing Alabama’s 4th Congressional District. He assumed office on January 3, 1997. His current term ends on January 3, 2027.

Aderholt (Republican Party) is running for re-election to the U.S. House to represent Alabama’s 4th Congressional District. He declared candidacy for the 2026 election.

Below is an abbreviated outline of Aderholt’s academic, professional, and political career:

1997-Present: U.S. Representative from Alabama’s 4th Congressional District
1995-1996: Staff for Governor Fob James of Alabama
1992-1995: Practiced law in Haleyville
1990: Graduated from Samford University with J.D.
1987: Graduated from Birmingham Southern College with B.A.
Prior to holding federal office, Aderholt was an aide to former Gov. Fob James (R) and served as a municipal judge in Haleyville, Alabama.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.